Comparison · NCT00424294-e145f5ad
Placebo and Celecoxib vs CP-195543 and Celecoxib: Number of Participants With Clinical Laboratory Abnormalities
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Placebo and Celecoxib vs CP-195543 and Celecoxib: Number of Participants With Clinical Laboratory Abnormalities. Trial comparisons, record NCT00424294-e145f5ad. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00424294-e145f5ad
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.429 | 0.28 | 0.591 | wilson | |
| Risk in group 2 | 0.412 | 0.264 | 0.578 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0168 | -0.206 | 0.237 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.598 | 1.81 | log | |
| Odds ratio, group 1 over group 2 | 1.07 | 0.412 | 2.79 | log | |
| Number needed to treat, for one more participant with the outcome on Placebo and Celecoxib than on CP-195543 and Celecoxib | 59.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Placebo and Celecoxib | Placebo matched to CP-195543 capsule orally twice daily along with celecoxib capsule 200 milligram (mg) orally twice daily for 12 weeks. A stable dose of methotrexate greater than or equal to (\>=) 10 milligram per week (mg/week) and less than or equal to (\<=) 25 mg/week via oral or parenteral route was continued as background therapy. | 15 | 35 | OG000 |
| Group 2 | CP-195543 and Celecoxib | CP-195543 capsule 400 mg orally twice daily along with celecoxib capsule 200 mg orally twice daily for 12 weeks. A stable dose of methotrexate \>=10 mg/week and \<=25 mg/week via oral or parenteral route was continued as background therapy. | 14 | 34 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Clinical Laboratory Abnormalities
- Description
Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick \[urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin\], microscopy \[urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous \[urine mucus and leucocytes\]).
- Time frame
- Baseline up to Week 13
- Population
- Safety analysis set is same as FAS. FAS was an intent-to-treat analysis set including all participants randomized to treatment who had taken at least 1 dose of study drug.
Source ClinicalTrials.gov
Trial
- Title
- A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
- NCT number
- NCT00424294
- Phases
- PHASE2
- Conditions
- Arthritis, Rheumatoid
- Interventions
- CP-195,543, celecoxib, Methotrexate
- Lead sponsor
- Pfizer
- Results first posted
- 2014-09-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00424294?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00424294-e145f5ad